Menu

ASX Announcements (2017)

29/11/2017 RNO: Completes $3.6 million capital raise
16/11/2017 RNO: Change in Substantial Holding
14/11/2017 RNO: Results Of General Meeting
01/11/2017 RNO: Joint Company Secretary Resignation
31/10/2017 RNO: Phoenix Healthcare to wholesale Mute in UK
23/10/2017 RNO: Completion of Test and Learn Program with US Retailer
14/09/2017 RNO: Rhinomed Signs Taiwanese Distributor
19/07/2017 RNO: Leading USA Pharmacy Takes Mute Into 4300 Stores
17/07/2017 RNO: Major Expansion of Mute USA Retail Footprint
06/07/2017 RNO: Rhinomed Receives Regulatory Clearance For Taiwan
05/07/2017 RNO: Letter to Small Shareholders
05/07/2017 RNO: Less Than Marketable Parcel Sale Facility
27/06/2017 RNO: Change of Address
10/05/2017 RNO: Change of Director’s Interest Notice
08/05/2017 RNO: Amcal and Guardian Core Range Mute Australia Wide
03/05/2017 RNO: Consolidation Timetable And ASX Code RNODC
06/04/2017 RNO: GNC USA to Sell Mute
29/03/2017 RNO: Change In Substantial Holding
29/03/2017 RNO: Notice of General Meeting-Proxy Form
29/03/2017 RNO: Notification of Consolidation-Split
21/03/2017 RNO: Appendix 3B
21/03/2017 RNO: Cleansing Prospectus
15/03/2017 RNO: Capital Management Initiatives
15/03/2017 RNO: Rhinomed Receives $280k Research And Development Tax Refund
15/03/2017 RNO: Rhinomed Completes Successful Capital Raise And Cornerstone Investment
08/03/2017 RNO: Mute Global Distribution Milestone Update
31/01/2017 RNO: Business Update & Appendix 4C
30/01/2017 RNO: Working Capital Facility